Important advances in the understanding of the biology and mechanisms of tumor
progression of urothelial carcinoma (UC) have been achieved over the past decade. The …

Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …

Abstract Context The European Association of Urology (EAU) guidelines panel on Muscle-
invasive and Metastatic bladder cancer (BCa) updates its guidelines yearly. This updated …

Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor
survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Background Despite aggressive local therapy, patients with locally advanced bladder
cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant …

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional …

Purpose To compare long-term survival in patients with locally advanced or metastatic
transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or …

Purpose The combination of gemcitabine plus cisplatin (GC) is a standard regimen in
patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested …

PURPOSE A prospective randomized trial was performed to determine if the addition of
methotrexate, vinblastine, and doxorubicin to cisplatin (M-VAC) imparted a response rate or …

Background Adjuvant chemotherapy is standard treatment for patients with resected colon
cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in …